{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "pubchem:21146529",
      "entity_text" : "tenofovir",
      "entity_type" : "simple_chemical"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uniprot:Q16270",
      "entity_text" : "TAF",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "TAF presents much better safety renal profile and reduces plasma tenofovir exposures by 90%, what decreases off-target side effects and has been shown to be significantly more stable in blood and plasma.",
  "reading_complete" : "2020-08-03T15:50:12Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T15:45:29Z",
  "trigger" : "reduces",
  "evidence" : [ "TAF presents much better safety renal profile and reduces plasma tenofovir" ],
  "pmc_id" : "5649484",
  "score" : 0
}